Get the Stockscreener App
6.47
4.02%
0.25
Novavax Inc stock is traded at $6.47, with a volume of 4.03M.
It is up +4.02% in the last 24 hours and down -24.68% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
See More
Previous Close:
$6.22
Open:
$6.25
24h Volume:
4.03M
Relative Volume:
0.79
Market Cap:
$1.05B
Revenue:
$1.08B
Net Income/Loss:
$422.82M
P/E Ratio:
2.8377
EPS:
2.28
Net Cash Flow:
$-637.33M
1W Performance:
-7.17%
1M Performance:
-24.68%
6M Performance:
-9.00%
1Y Performance:
-19.53%
1-Day Range:
$6.245
$6.54
1-Week Range:
$6.20
$6.979
52-Week Range:
$5.01
$11.55
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Compare NVAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
6.47 | 1.01B | 1.08B | 422.82M | -637.33M | 2.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-25 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-28-25 | Resumed | H.C. Wainwright | Buy |
| Aug-20-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-17-25 | Initiated | Citigroup | Sell |
| Feb-28-25 | Initiated | BTIG Research | Buy |
| Jul-30-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-10-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-10-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
Behavioral Patterns of NVAX and Institutional Flows - news.stocktradersdaily.com
Novavax, UniFirst, and More Stocks See Action From Activist Investors - Barron's
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax rises after a seven-day slide - MSN
Interesting NVAX Put And Call Options For July 2026 - Nasdaq
How rising interest rates impact Novavax Inc. stockWeekly Risk Report & Reliable Intraday Trade Alerts - newser.com
Is Novavax Inc. stock undervalued vs historical averagesJuly 2025 Reactions & Weekly Hot Stock Watchlists - newser.com
Will Novavax Inc. (NVV1) stock hit Wall Street targets2025 Analyst Calls & Low Volatility Stock Suggestions - newser.com
Why Novavax Inc. stock appeals to dividend seekers2025 Fundamental Recap & AI Powered Trade Plan Recommendations - newser.com
How Novavax Inc. (NVV1) stock gains from tech spendingOptions Play & Risk Controlled Stock Pick Alerts - newser.com
Is Novavax Inc. stock a buy on dipsJuly 2025 Short Interest & Long-Term Growth Plans - newser.com
earlytimes> 2025> Is Novavax Inc a good long term investmentCash Flow Trends & Small Investment Wealth Growth - earlytimes.in
Published on: 2025-11-20 05:45:01 - newser.com
Will Novavax Inc. stock maintain growth storyJuly 2025 Highlights & Real-Time Volume Analysis - newser.com
Will Novavax Inc. (NVV1) stock split increase liquidityEarnings Risk Report & Technical Confirmation Alerts - newser.com
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Published on: 2025-11-19 15:40:01 - newser.com
Notable Wednesday Option Activity: NVAX, BLK, MP - Nasdaq
Why pension funds invest in Novavax Inc. (NVV1) stockTrade Volume Report & Scalable Portfolio Growth Methods - newser.com
NVAX: Strategic partnerships and Matrix-M platform drive growth, targeting major vaccine markets - TradingView
Novavax at Jefferies London: Strategic Shift to Partnerships By Investing.com - Investing.com Canada
Is Novavax Inc. stock in correction or buying zoneJuly 2025 Review & Real-Time Market Sentiment Alerts - newser.com
Can Novavax Inc. stock rebound after recent weaknessJuly 2025 Technicals & Low Risk Entry Point Guides - newser.com
Market reaction to Novavax Inc.’s recent newsTrade Entry Summary & Entry Point Strategy Guides - newser.com
How Novavax Inc. stock compares to market leadersQuarterly Portfolio Report & Long-Term Growth Portfolio Plans - newser.com
Will breakout in Novavax Inc. lead to full recoveryMarket Performance Summary & AI Driven Price Forecasts - newser.com
Relative strength of Novavax Inc. in sector analysis2025 Top Decliners & Risk Controlled Daily Plans - newser.com
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):